CD9 and prostate carcinoma: We also found that the content of CD9 positive EV in plasma of prostate cancer patients was higher than for BPH patients, warranting further analysis in larger patient cohorts to validate plasma derived CD9 positive EV as potential prostate cancer biomarkers.